S

TKI Targeted Therapy for NSCLC With ALK, ROS1 & NTRK Mutations: Surveying Safety Data, Sequencing and Resistance

By Susanne Arnold 4 Videos
167 views
May 3, 2021
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
35:40
Balazs Halmos

Year in Review: Lung Cancer

27:04
Fengting Yan

Cancer Screening Molecular Tools

25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

07:43
Yale Cancer Center

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Feat. P. Janne
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
20:52
Total Health

Diagnostics in Lung Cancer: A Comprehensive Discussion - Best of Lun…

Feat. T. Boyle
14:49
Vivek Subbiah

Year in Review: Precision Medicine

05:02
GRACE

Targeted Therapies in Lung Cancer 2023: Biomarkers in NSCLC

Feat. A. Desai
16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
23:32
2023 West Oncology Conference

2023 Updates on Neoadjuvant and Adjuvant NSCLC

Feat. M. Johnson
11:50
GRACE

The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies

Feat. J. Rotow
22:57
Total Health

Lung Cancer Screening - Best of Lung 2023

Feat. C. Olazagasti
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
08:30
Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard
54:26
Yale Cancer Center

Year in Review: Progress in NSCLC Treatment

Feat. R. Herbst
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst